Alitair Pharmaceuticals

Alitair Pharmaceuticals is a specialty pharmaceutical company dedicated to addressing unmet medical needs in the respiratory space. Through their proprietary ion-exchange resin formulations and prescription cough medicines, as well as a pipeline of orphan drugs, they aim to provide innovative solutions for patients. The company has a robust pipeline, including a patented Overdose Reduction formulation (ODR) designed to mitigate the risk of prescription drug overdose, and plans for internal product development, out-licensing opportunities, and strategic partnerships to further their corporate goals. Established in 2010, Alitair is focused on expanding its presence in the global pharmaceutical market. For more detailed information on the company, its pipeline, and business development strategies, please visit their website.